Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Head and Neck Neoplasms 7 Neoplasms 3 Thyroid Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Hypoparathyroidism 2 Carcinoma, Squamous Cell 2 Vulvar Neoplasms 1 Uterine Cervical Neoplasms 1 Thyroid Diseases 1 Recurrence 1 Rectal Neoplasms 1 Parathyroid Diseases 1 Ovarian Neoplasms 1 Neovascularization, Pathologic 1 Melanoma 1 Margins of Excision 1 Lymphedema 1 Head and Neck Carcinoma 1 Graves Disease 1 Goiter 1 Endometrial Neoplasms 1 Breast Neoplasms 1 Anus Neoplasms 1 Adenoma 1

Interventions

Cetuximab 14 Cisplatin 12 pembrolizumab 11 Paclitaxel 9 Gemcitabine 9 durvalumab 6 Nivolumab 6 Docetaxel 6 toripalimab 5 Carboplatin 5 Radiotherapy 4 Fluorouracil 4 Cyclophosphamide 4 fludarabine 3 Valproic Acid 3 Capecitabine 3 tremelimumab 2 spartalizumab 2 nimotuzumab 2 irinotecan sucrosofate 2 fludarabine phosphate 2 cemiplimab 2 anlotinib 2 Sunitinib 2 S 1 (combination) 2 Radiation 2 Oxaliplatin 2 NVP-BKM120 2 Methotrexate 2 Ipilimumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Indocyanine Green × Head & Neck × Clear all

NCT02920216 2022-03-31

SALVADS-Fluo

Institut de Cancérologie de Lorraine

Phase NA Completed

Head and Neck Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡